Prof. Dr. MURAT SARI

1. First-Line Treatment After Perioperative FLOT in Recurrent Gastric and Gastroesophageal Junction Cancer: A Turkish Oncology Group (TOG) Multicenter Real-World Analysis

Seyyar M., Can Şancı P., SAKİN A., Bayramgil A., Dülgar Kaya Ö., SÜNGER E., et al.

Medicina (Lithuania) , cilt.62, sa.5, 2026 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

2. Multicenter Real-World Evaluation of Neoadjuvant Carboplatin in Triple-Negative Breast Cancer

Ellez H. İ., ÇalişkanYildirim E., Majidova N., AĞYOL Y., SARI M., SEMİZ H. S., et al.

Cancer Medicine , cilt.15, sa.5, 2026 (SCI-Expanded, Scopus)

3. Prognostic Impact of Early Metabolic Response on Interim 18F-FDG PET/CT in HR+/HER2− Metastatic Breast Cancer Treated with CDK4/6 Inhibitors

Aliyev V., Güren A. K., Guliyev M., Birsin Z., Günaltılı M., Fidan M. C., et al.

Medicina (Lithuania) , cilt.62, sa.3, 2026 (SCI-Expanded, Scopus)

4. Trastuzumab Deruxtecan–Induced Interstitial Lung Disease: A Systematic Review and Meta-Analysis of Clinical Trials and Real-World Evidence

Güren A. K., DEMİRCAN N. C., SARI M., KÖSTEK O., BAYOĞLU İ. V.

Cancer Control , cilt.33, 2026 (SCI-Expanded, Scopus)

5. Prognostic Value of 18F-FDG PET/CT-Derived Secondary Lymphoid Organ Ratios and Hematologic Inflammation Markers in Advanced Non-Small Cell Lung Cancer Treated with Nivolumab

KOCAASLAN E., Güren A. K., Akagündüz F., DEMİREL A., TUNÇ M. A., PAÇACI B., et al.

Journal of Clinical Medicine , cilt.15, sa.2, 2026 (SCI-Expanded, Scopus)

6. Prognostic Value of Treatment-Related Body Composition Changes in Metastatic NSCLC Receiving Nivolumab

KOCAASLAN E., Güren A. K., Akagündüz F., DEMİREL A., TUNÇ M. A., PAÇACI B., et al.

Medicina (Lithuania) , cilt.62, sa.1, 2026 (SCI-Expanded, Scopus)

7. Adult-Onset Diffuse Midline Glioma, H3K27-Altered: A Genomics-Guided, Individualized, Multimodal Treatment Approach

Çelebi A., Yıldırım B., Yıldırım E., Işık S., ÇOBAN E., BIYIKLI E., et al.

Brain Sciences , cilt.16, sa.1, 2026 (SCI-Expanded, Scopus)

8. Prognostic Value of Systemic Immune-Inflammation Index in Mucosal Malignant Melanoma

PAÇACI B., KOCAASLAN E., DEMİREL A., Akagündüz F., TUNÇ M. A., AĞYOL Y., et al.

Journal of Clinical Medicine , cilt.15, sa.2, 2026 (SCI-Expanded, Scopus)

9. Integration of ımmunotherapy in limited-stage small cell lung cancer: a review of the literature

Güren A. K., DEMİRCAN N. C., SARI M., KÖSTEK O.

Current Medical Research and Opinion , cilt.42, sa.1, ss.87-97, 2026 (SCI-Expanded, Scopus)

10. Capecitabine versus Paclitaxel After CDK4/6 Inhibitor Progression in Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer: A Real-World Study

Birsin Z., Güren A. K., Aliyev V., Guliyev M., Jeral S., Cebeci S., et al.

Breast Cancer: Targets and Therapy , cilt.18, 2026 (SCI-Expanded, Scopus)

11. Systemic Anticancer Therapy Near the End of Life: Association of Treatment Escalation With Hospital-Centered Care in Metastatic Cancer: A Retrospective Cohort Study

Çoban E., SARI M., Çelik S., Öven B. B.

American Journal of Hospice and Palliative Medicine , 2026 (SCI-Expanded, Scopus)

12. YAU-RCC spotlight: dual VEGF/EGFR blockade shows promise for reshaping the treatment of papillary RCC in hereditary leiomyomatosis and renal cell cancer syndrome

ERDEM S., SARI M., Marandino L., Flippot R., Amparore D., Campi R.

Minerva urology and nephrology , cilt.77, sa.5, ss.587-591, 2025 (SCI-Expanded, Scopus)

13. The Role of Baseline PET/CT Parameters in Predicting Treatment Response in Patients with Locally Advanced Rectal Cancer Undergoing Total Neoadjuvant Therapy

Güren A. K., Başkan Z., Balaban Genç Z. C., Bulun Akyol T., Kocaaslan E., Ağyol Y., et al.

MEDICINA-LITHUANIA , cilt.61, sa.8, 2025 (SCI-Expanded, Scopus)

14. Clinical and Demographic Features in Malignant Peritoneal Mesothelioma: Treatment Approaches and Factors Affecting Survival

SEVER N., Yildirim S., Gürbüz A. F., Karakaş Kiliç D., Zeynelgil E., Altintaş Y. E., et al.

Journal of Oncological Science , cilt.11, sa.2, ss.104-111, 2025 (Scopus, TRDizin)

15. Clinicopathological features and treatment outcomes of patients with fibrolamellar hepatocellular carcinoma: a retrospective multicenter study.

Polat H., Çoban E., Çerme E., Kahveci G. B., Geçgel A., Dama P. E., et al.

Annals of Saudi medicine , cilt.45, sa.4, ss.249-255, 2025 (SCI-Expanded, Scopus)

16. Clinicopathological Features and Survival Outcomes of Colorectal Cancer Patients Under 40 Years: A 20-Years Single-Center Experience

Kaan A., Demircan N. C., ÖZGÜR S. Ş., AKYOL T. B., majıdova n., Kocaaslan E., et al.

Uluslararası Hematoloji-Onkoloji Dergisi , cilt.35, sa.2, ss.104-111, 2025 (SCI-Expanded, Scopus, TRDizin)

17. “Pre-Treatment“ and “Post-Treatment” Systemic Inflammatory Markers: Is There Any Prognostic Role for Metastatic Cervical Cancer on Bevacizumab Containing Treatment?

Yaşar S., Kadıoğlu A., Akyildiz A., SEVER N., Büyükbayram M. E., BİLİCİ M., et al.

Medicina (Lithuania) , cilt.61, sa.6, 2025 (SCI-Expanded, Scopus)

18. Darolutamide: A New Hope in the Battle Against Prostate Cancer Plain Summary

Sari M., Köstek O.

Eurasian Journal of Medical Investigation , cilt.9, sa.1, ss.1-11, 2025 (TRDizin)

19. Evaluation of Pancreatic Atrophy in Patients with Hepatocellular Carcinoma Receiving Sorafenib Treatment

Kaan A., Zengin G., majıdova n., SEVER N., Ergelen R., Köstek O., et al.

Eurasian Journal of Medical Investigation , cilt.9, sa.1, ss.29-35, 2025 (TRDizin)

20. Kas-İnvaziv mesane kanserinde neoadjuvan ve adjuvan kemoterapinin sağkalım üzerine etkinliği: Çok merkezli çalışma

majıdova n., Öztürk A. E., Çolak R., yalıcı ö., İÇLİ M. C., KÖKSAL B., et al.

Turkish Journal of Clinics and Laboratory , cilt.16, sa.1, ss.123-130, 2025 (TRDizin)

21. Prognostic Factors in High Grade Osteosarcoma Patients Who Received Neoadjuvant Therapy and Subsequently Underwent Surgery: Data from the Turkish Oncology Group

SEVER N., ŞİMŞEK F., Onur İ. D., Arvas H., GULIYEV T., Şakalar T., et al.

Journal of Clinical Medicine , cilt.14, sa.6, 2025 (SCI-Expanded, Scopus)

22. Sex-related disparities in outcomes of survival in biliary tract cancer patients.

Sever N., Yunusov E., Majidova N., Kocaaslan E., Erel P., Ağyol Y., et al.

Journal of cancer research and clinical oncology , cilt.151, sa.2, ss.95, 2025 (SCI-Expanded, Scopus)

23. Evaluation of Dose Reduction Factors and Impact on Progression-Free Survival in Patients Treated with CDK 4/6 Inhibitors

Güren A. K., Guliyev M., Alan Ö., Çadırci K., Belevi İ. N., Gültürk İ., et al.

Journal of Clinical Medicine , cilt.14, sa.4, 2025 (SCI-Expanded, Scopus)

24. The Effect of Systemic Inflammation and Clinicopathologic Features on Survival in Malignant Pleural Mesothelioma: A Multicenter Analysis

SEVER N., Yıldırım S., Gurbuz A. F., Karakaş Kılıç D., Zeynelgil E., Altintaş Y. E., et al.

Medicina (Lithuania) , cilt.61, sa.1, 2025 (SCI-Expanded, Scopus)

25. Sorafenib vs chemotherapy in the treatment of locally advanced or metastatic, radioactive iodine-refractory differentiated thyroid cancer: real-world data from Turkey

Majidova N., Aghamaliyeva S., Guliyev M., Dinc G., Akyıldız A., Ozcan E., et al.

Journal of Chemotherapy , cilt.37, sa.8, ss.735-740, 2025 (SCI-Expanded, Scopus)

26. Avelumab maintenance in patients with metastatic urothelial carcinoma in a real-life expanded-access program

Tural D., Özkan O., Eylemer Mocan E., Kapar C., YASLIKAYA Ş., TATLI A. M., et al.

Future Oncology , cilt.21, sa.27, ss.3499-3505, 2025 (SCI-Expanded, Scopus)

27. The Effect of PET/CT SUV max Value on Anti-EGFR Treatment Response in Lung Adenocarcinoma

Ercelep O., Isik S., ERCAN E., KÖSTEK O., Bayoglu V., Celebi A., et al.

UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi , cilt.35, sa.3, ss.159-165, 2025 (SCI-Expanded, Scopus)

28. Impact of Sarcopenia and Osteopenia on Prognosis in Metastatic Biliary Tract Cancer: A Single Center Experience.

Sever N., Yunusov E., Çağlar E. İ., Çelebi A., Majidova N., Kocaaslan E., et al.

Nutrition and cancer , cilt.77, sa.6, ss.610-618, 2025 (SCI-Expanded, Scopus)

29. Comparison of the efficacy of sunitinib and pazopanib in patients with advanced non-clear renal cell carcinoma

Yildirim H. C., Bayram E., Chalabiyev E., Majidova N., Avci T., Güzel H. G., et al.

Journal of Chemotherapy , cilt.37, sa.6, ss.551-562, 2025 (SCI-Expanded, Scopus)

30. Which factors help to determine the long-term response to first-line tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma: A Turkish multicenter study

Majidova N., Seyyar M., Bayraktar D. I., Dinç G., İsgandarov E., Huseynov J., et al.

Biomolecules and Biomedicine , cilt.24, sa.6, ss.1776-1784, 2024 (SCI-Expanded, Scopus)

31. The Prognostic Importance of Clinicopathological Factors in Patients with Osteosarcoma Who Received Neoadjuvant Therapy; A Single Center Experience

Simsek F., majıdova n., Kircali M. F., SEVER N., çelebi a., ARIKAN R., et al.

Eurasian Journal of Medical Investigation , cilt.8, sa.3, ss.184-192, 2024 (TRDizin)

32. HER2 exon 20 mutant non-small cell lung cancer with complete remission of intracranial metastases with trastuzumab deruxtecan: A case report

Güren A. K., KOCAASLAN E., AĞYOL Y., Majidova N., Sever N., EREL P., et al.

Anti-Cancer Drugs , cilt.35, sa.8, ss.769-773, 2024 (SCI-Expanded, Scopus)

33. Clinicopathologic Features and Efficacy of Induction Chemotherapy in Nasopharyngeal Carcinoma: Real-World Experience

Majidova N., SARI M., Kahvecioglu F. A., Ozcan E., Akdag M. O., Dogan A., et al.

Oncology Research and Treatment , cilt.47, sa.7-8, ss.360-367, 2024 (SCI-Expanded, Scopus)

34. The Effectiveness of Adjuvant PD-1 Inhibitors in Patients With Surgically Resected Stage III/IV Acral Melanoma

Arak H., Erkiliç S., YASLIKAYA Ş., EYLEMER MOCAN E., Aktaş G., Özdemir M., et al.

Journal of immunotherapy (Hagerstown, Md. : 1997) , cilt.47, sa.5, ss.182-189, 2024 (SCI-Expanded, Scopus)

35. Systemic Inflammation Response Index and Pan-Immune-Inflammation Value: Prognostic Significance in Metastatic Melanoma

Majidova N., Kircali M. F., Güren A. K., Sever N., KOCAASLAN E., AĞYOL Y., et al.

Journal of Oncological Science , cilt.10, sa.3, ss.144-149, 2024 (Scopus, TRDizin)

36. Prognostic Factors Associated with Resected Osteosarcoma: Efficacy of Adjuvant Setting, Real-World Experience

Majidova N., ŞİMŞEK F., Biter S., YASLIKAYA Ş., Seyyar M., DUYGULU M. E., et al.

UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi , cilt.34, sa.1, ss.20-27, 2024 (SCI-Expanded, Scopus, TRDizin)

37. The effect of parity, breastfeeding history, and duration on clinical and pathological characteristics of breast cancer patients

Ak N., Tuz Z., Aydin E., Ferhatoğlu F., SARI M., Paksoy N., et al.

Turkish Journal of Medical Sciences , cilt.54, sa.1, ss.229-238, 2024 (SCI-Expanded, Scopus, TRDizin)

38. The prognostic factors in patients with advanced hepatocellular carcinoma: impact of treatment sequencing

KÖSTEK O., DEMİREL A., Hacıoğlu M. B., TAŞTEKİN D., KARABULUT S., Gündogdu A., et al.

Journal of Chemotherapy , cilt.36, sa.7, ss.613-621, 2024 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

39. Evaluation of Clinicopathological Characteristics and Survival Outcomes of Young Gastric Cancer Patients, Single Center Experience

ARIKAN R., Telli T. A., ışık s., Sari M., Köstek O., Ercelep Ö., et al.

Eurasian Journal of Medical Investigation , cilt.7, sa.3, ss.296-302, 2023 (TRDizin)

40. PNI as a Potential Add-On Biomarker to Improve the IMDC Intermediate Prognostic Score

BAYOĞLU İ. V., Hüseynov J., Topal A., Sever N., Majidova N., Çelebi A., et al.

Journal of Clinical Medicine , cilt.12, sa.19, 2023 (SCI-Expanded, Scopus)

41. The effect of low HER2 expression on treatment outcomes in metastatic hormone receptor positive breast cancer patients treated with a combination of a CDK4/6 inhibitor and endocrine therapy: A multicentric retrospective study

ÇALIŞKAN YILDIRIM E., ATAĞ E., Coban E., Umit Unal O., Celebi A., Keser M., et al.

Breast , cilt.70, ss.56-62, 2023 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

42. Prognostic Significance of Mucinous Histology in Metastatic Colorectal Cancer Patients Treated with Regorafenib

ARIKAN R., Üstün H. S., Demircan N. C., Işik S., Telli T. A., Yaşar A., et al.

Journal of Oncological Science , cilt.9, sa.2, ss.53-61, 2023 (Scopus, TRDizin)

43. Syrian Refugee and Turkish Women with Breast Cancer: A Comparison on Clinicopathological Features and Survival

ATAĞ AKYÜREK E., Gokcay S., Simsek E. T., Aslan F., Yetisir A. E., Sari M.

Archives of Iranian Medicine , cilt.26, sa.1, ss.29-35, 2023 (SCI-Expanded, Scopus)

44. The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early-stage human epidermal growth factor receptor 2-positive breast cancer: Turkish Oncology Group study

Ozdemir O., Zengel B., Yildiz Y., Uluc B. O., ÇABUK D., Ozden E., et al.

ANTI-CANCER DRUGS , cilt.33, sa.7, ss.663-670, 2022 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

45. Deficient Mismatch Repair and Lymphocytic Response to Tumor as Prognostic Markers in Stage II Colon Cancer Patients

Sari M., ATAĞ AKYÜREK E., Demir T., Simsek E. T., Coban E., Cikrikcioglu M.

Journal of the College of Physicians and Surgeons Pakistan , cilt.32, sa.2, ss.186-192, 2022 (SCI-Expanded, Scopus)

46. The Effect of FDG-PET/CT on Clinical Prognostic Staging of Breast Cancer Patients being Planned Neoadjuvant Treatment

Simsek E. T., Coban E., ATAĞ AKYÜREK E., Gungor S., Aker F., Sari M.

Journal of the College of Physicians and Surgeons Pakistan , cilt.32, sa.2, ss.181-185, 2022 (SCI-Expanded, Scopus)

47. The role of fdg pet/ct to evaluation of axillary lymph nodes after neoadjuvant chemotherapy in breast cancer

Simsek E. T., Coban E., ATAĞ AKYÜREK E., Gungor S., Sari M., Gurleyik G.

Journal of the College of Physicians and Surgeons Pakistan , cilt.31, sa.7, ss.792-797, 2021 (SCI-Expanded, Scopus)

48. Rapid drug desensitization for platinum-based chemotherapy drugs significantly increases peripheral blood IL-10 levels

Tüzer C., Sari M., ÇETİN E., AK N., Büyüköztürk S., Çolakoğlu B., et al.

Allergy: European Journal of Allergy and Clinical Immunology , cilt.75, sa.11, ss.2942-2945, 2020 (SCI-Expanded, Scopus)

49. Extra-abdominal aggressive fibromatosis treated with meloxicam and sorafenib: An encouraging option

Sari M.

Journal of Cancer Research and Therapeutics , cilt.16, sa.4, ss.900-902, 2020 (SCI-Expanded, Scopus)

50. Rare mutations of epidermal growth factor receptor in epidermal growth factor receptor-tyrosine kinase inhibitor-naive non-small cell lung carcinoma and the response to erlotinib therapy

Sari M., Aydiner A.

Journal of Cancer Research and Therapeutics , cilt.16, sa.1, ss.132-138, 2020 (SCI-Expanded, Scopus)

51. Eribulin monotherapy in heavily pretreated metastatic breast cancer patients in real life

Sari M., Saip P.

Indian journal of cancer , cilt.57, sa.1, ss.55-61, 2020 (SCI-Expanded, Scopus)

52. Efficacy of palbociclib and endocrine treatment in heavily pretreated hormone receptor-positive/HER2-negative advanced breast cancer: Retrospective multicenter trial

Demir A., Mandel N. M., Paydas S., Demir G., Er Ö., Turhal N. S., et al.

Balkan Medical Journal , cilt.37, sa.2, ss.104-107, 2020 (SCI-Expanded, Scopus, TRDizin)

53. Comparison between body composition parameters and response to neoadjuvant chemotherapy by using pre-treatment PET CT in locally advanced breast cancer

KIZILDAĞ YIRGIN İ., Has D., Arslan G., AYDIN E., Sari M., Onder S., et al.

European Journal of Radiology Open , cilt.7, 2020 (ESCI, Scopus)

57. The effect of suppressed levels of uninvolved immunoglobulins on the prognosis of symptomatic multiple myeloma Hastalıkla İlişkili Olmayan İmmünglobulin Düzeylerindeki Baskılanmanın Multipl Miyelomda Prognoz Üzerine Etkisi

Sarı M., Sarı S., Nalçacı M.

Turkish Journal of Hematology , cilt.34, sa.2, ss.131-136, 2017 (SCI-Expanded, Scopus, TRDizin)

58. Is inferior vena caval filter an alternative treatment option for geriatric patients that cannot use anticoagulation therapy?

Akın S., Sari M., Tufan F., BAHAT-ÖZTÜRK G., Saka B., Erten N., et al.

Aging Clinical and Experimental Research , cilt.26, sa.1, ss.73-75, 2014 (SCI-Expanded, Scopus)

Yayınlar & Eserler